慢性腎疾患の進行におけるNEAT1/miR-124-3p/CCL2軸:統合生物情報分析と実験的検証
Guanting Chen1,2, Linqi Zhang1,2, Yaoxian Wang2
1Department of Nephrology, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China.
Epigenomics
|August 21, 2025
まとめ
研究者は,CCL2を含む重要な遺伝子を,慢性腎臓病 (CKD) の潜在的なバイオマーカーおよび治療標的として特定しました. NEAT1,miR-124-3p,CCL2を含む規制軸は,CKDの進行において極めて重要であることが判明した.
科学分野:
- 腎臓科
- 分子生物学
- ゲノミクス
背景:
- 慢性腎臓病 (CKD) は 世界的に深刻な健康問題であり 治療の効果は限られている.
- 腎臓インタースティシャル線維症 (RIF) は,CKDの進行の主な要因です.
- この研究は,慢性腎臓病の新たな診断バイオマーカーと治療目標の発見を目指した.
研究 の 目的:
- 異なる発現遺伝子 (DEGs) とCKDにおける重要な調節経路を特定する.
- 様々な実験モデルと臨床サンプルを使用して,潜在的なバイオマーカーと治療標的を検証する.
- NEAT1/miR-124-3p/CCL2軸がCKDの病原性における役割を明らかにする.
主な方法:
- DEGを特定するためにGEOデータセット GSE137570の分析.
- ハブ遺伝子をスクリーニングするためのタンパク質相互作用 (PPI) ネットワークの構築.
- 競合する内生RNA (ceRNA) ネットワークの予測と単細胞配列決定,インビトロEMTモデル,臨床サンプル,二重ルシフェラゼレポーター測定 (DLRA) による検証.
主要な成果:
- 5つのハブ遺伝子 (EGF,VCAN,CXCL1,MMP7,CCL2) が特定され,CCL2が最も中心的であった.
- 濃縮分析は,これらの遺伝子と免疫/炎症反応の関連性を示した.
- NEAT1/ miR- 124 - 3p/ CCL2軸が確認され,血清のCCL2が増加し,miR- 124 - 3pとNEAT1はCKDの進行とともに減少した.これらの要因は診断の正確性を示した.
結論:
- CCL2はEGF,VCAN,CXCL1,MMP7と共に,CKDのバイオマーカーと治療標的として有望である.
- NEAT1/miR-124-3p/CCL2軸は,CKDに関与する重要な調節経路である.
- バイオインフォマティクスと臨床コホートにおける適度なサンプルサイズは,将来の研究にとって重要な制限を意味します.
関連する概念動画
01:25Chronic Kidney Disease I: Introduction
67
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
67
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
01:28Chronic Kidney Disease III: Interprofessional Care
78
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
78
01:29Acute Kidney Injury II: Pathophysiology
72
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
72
01:24Chronic Kidney Disease II: Clinical Manifestations
87
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
87